@JICE_EP is pleased to announce its new 2024 Impact Factor of 2.6
Follow Us - All articles available for download @JICE_EP
Submit your science at https://t.co/UZicUvVSh0
@DavidDuncker Lieber David, herzlichste Glückwünsche zur W2-Professur 👏🏼
Ein exzellentes Beispiel bei dem sich Kontinuität, Leidenschaft und Klarheit auszahlen.
1/ Flecainide monotherapy: Risks you need to know ⚡💊
While effective for rhythm control, flecainide carries serious risks—especially when used without an AV nodal blocker. Here’s why. 🧵👇
#Cardiology#AtrialFibrillation#Flecainide
Among patients with ventricular tachycardia and ischemic cardiomyopathy, catheter ablation as an initial therapy led to a lower risk of adverse outcomes than antiarrhythmic drug therapy. Read the full VANISH2 trial results: https://t.co/yDFhCI9KNA
#cardiology
Congratulations to @johnlsapp on the presentation and publication of VANISH-2.
First line VT ablation is associated with significant reduction in composite of death, VT, storm for patients with ischemic cardiomyopathy.
https://t.co/STIy0J708f
New 2024 #ESCGuidelines on #Afib
🆕Class IA recommendation:
Catheter ablation for AF now recommended as a first-line option within a shared decision-making rhythm control strategy in paroxysmal AF
#ESCCongress@escardio